
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-10-07-2015
- Volume 11
- Issue 10
Cobra Biologics Announces Scale-Up Collaboration
Cobra Biologics and the University of Manchester announce a collaboration to improve industrial scale-up of mammalian cell bioprocessing.
Cobra Biologics and Alan Dickson, professor of biotechnology at The University of Manchester (UoM) announced on Sept. 24, 2015 a two-year collaboration focused on improving understanding of cellular bioprocessing required for the scaled production of therapeutic proteins. The collaboration is supported through the FLexible Interchange Programme (FLIP) Scheme from the Biotechnology and Biological Sciences Research Council (BBSRC).
The partnership will address the need for greater predictability and certainty in process development and scale-up for the production of protein-based biopharmaceuticals for application in therapeutic areas including cancer and inflammation, according to a Cobra Biologics press announcement.
The agreement will give Cobra access to the UoM’s academic and associated research group. Professor Dickson will have access to Cobra’s production data and operational knowledge of industrial manufacturing processes. Financial terms and terms relating to IP have not been disclosed.
Source:
Articles in this issue
almost 11 years ago
Cost Inhibits CMO Adoption of Single-Use Equipmentalmost 11 years ago
Low Temperature Needed for Complex Drug Candidatesalmost 11 years ago
FDA Plans Pilot Projects for Drug Supply Chain Security Actalmost 11 years ago
Vetter Embarks on 300-Million Euro Manufacturing Expansionalmost 11 years ago
Sterigenics International Adds Capacityalmost 11 years ago
Tecnandina’s Ecuador Facility Receives ANVISA Certificationalmost 11 years ago
Hovione Expands Drug Substance Manufacturingalmost 11 years ago
Piramal Introduces Proof of Concept Service for Next Wave of ADC Growthalmost 11 years ago
Patheon Unveils New Brand Identityalmost 11 years ago
FDA Releases Guidance on Generic-Drug Development


